agr2 Antibody

What is AGR2 and why is it significant in cancer research?

AGR2 belongs to the protein disulfide isomerases family and resides in the endoplasmic reticulum (ER) where it maintains protein folding and proteostasis. It is significantly overexpressed in multiple cancer types including pancreatic, breast, ovarian, prostate and esophageal cancers, making it an important biomarker and therapeutic target . AGR2 has been demonstrated to promote tumor progression through various mechanisms, including enhancing cell adhesion, motility, and invasiveness . In normal tissues, AGR2 is primarily expressed in intestinal cells and the epithelium of the digestive tract, with minimal expression in most other tissue systems .

What types of AGR2 antibodies are currently available for research?

Several types of AGR2 antibodies have been developed for research applications:

• Standard monoclonal antibodies - Such as the AGR2 (D9V2F) XP® Rabbit mAb, which recognize endogenous levels of total AGR2 protein

• High-affinity fully human monoclonal antibodies - Developed through phage display library screening and affinity maturation processes, with binding affinities in the picomolar range

• Bispecific antibodies - Including the novel AGR2xPD1 BsAb that simultaneously targets AGR2 and PD1, designed to redirect cytotoxic T-cells to AGR2-expressing tumors

• Single-chain variable fragments (scFvs) - Smaller antibody fragments that retain antigen-binding capacity

In which cancer types is AGR2 expression most relevant?

AGR2 is overexpressed in numerous adenocarcinomas. Research studies have found significant AGR2 overexpression in:

• Pancreatic ductal adenocarcinoma (PDAC) (approximately 90% of cases)

• Breast cancer

• Ovarian cancer

• Prostate cancer

• Esophageal cancer

In pancreatic tissue, AGR2 expression increases with disease progression, being detected in 100% of pancreatic intraepithelial neoplasia (PanIN) lesions with increasing expression levels from PanIN1 to PanIN3, while remaining undetectable in normal pancreatic tissue .

What are the recommended protocols for using AGR2 antibodies in different applications?

AGR2 antibodies can be utilized across multiple applications with the following recommended dilutions and protocols:

Western Blotting (WB):

• Recommended dilution: 1:500-1:2000 or 1:1000 depending on the specific antibody

• Detects AGR2 at approximately 18 kDa

Immunohistochemistry (IHC):

• Recommended dilution: 1:50-1:500 or 1:800 depending on the antibody

• Protocol for paraffin sections: Use 4-μm thick sections with TE buffer pH 9.0 or citrate buffer pH 6.0 for antigen retrieval

• Detection systems: DABMap kit for Ventana Discovery System with hematoxylin counterstaining

Immunofluorescence (IF):

• Recommended dilution: 1:50-1:500 or 1:100 depending on the antibody

Flow Cytometry (FC):

• Recommended dilution: 1:50 or 0.40 μg per 10^6 cells in 100 μl suspension

• Protocol: Harvest cells with trypsin/EDTA, resuspend in appropriate buffer (DMEM with 0.1% BSA and 0.1% sodium azide), incubate with primary antibody on ice for 45 minutes, detect with fluorophore-conjugated secondary antibody

Immunoprecipitation (IP):

• Recommended amount: 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

How should AGR2 expression be evaluated in tissue samples?

For quantitative assessment of AGR2 expression in tissue samples, researchers should use a combined scoring system:

• Intensity scoring:

  • Grade on a scale from 0 to 3 (0 = no staining, 3 = strong staining)

• Extent scoring based on percentage of stained cells:

  • 0 points: no staining

  • 1 point: <20% stained cells

  • 2 points: 20%-50% stained cells

  • 3 points: >50% stained cells

• Total score calculation:

  • Multiply intensity score by extent score

  • Interpretation: 0-3 = negative/weakly positive; 4-6 = moderately positive; >6 = strongly positive

This scoring system allows for standardized assessment across different studies and tissue types, as demonstrated in the table below for pancreatic lesions:

What controls should be used when working with AGR2 antibodies?

Positive controls:

• A549 cells (positive in WB, IP, IF/ICC, and FC)

• Rat colon and stomach tissue (positive in WB)

• Mouse stomach tissue (positive in WB)

• Human colon tissue (positive in IHC)

• Human breast cancer tissue (positive in IHC)

Negative controls:

• Normal pancreatic tissue (negative for AGR2)

• Other non-digestive tract normal tissues (minimal AGR2 expression)

How does AGR2 promote tumor progression at the molecular level?

AGR2 promotes tumor progression through multiple mechanisms:

• Oncogenic transformation in the tumor microenvironment:

  • AGR2 interacts with neighboring fibroblasts to induce oncogenic changes

  • Functions as both an intracellular protein and a secreted extracellular factor

• Enhanced cellular functions:

  • Increases adhesion, motility, and invasiveness of cancer cells

  • Promotes cell growth, division, and transformation

• Signaling pathway modulation:

  • Induces PDL1 upregulation through EGFR signaling pathway

  • Functions involve YAP1-mediated up-regulation of amphiregulin expression, implicating AGR2 in both EGF and Hippo kinase signaling pathways

  • Expression is inversely related to SMAD4 status in PDAC and colorectal cancer

• Proteolytic regulation:

  • Promotes cancer cell dissemination through regulation of cathepsins B and D

• Angiogenesis promotion:

  • AGR2 contributes to tumor vascularization

What are the mechanisms of action for AGR2-targeting therapeutic antibodies?

AGR2-targeting antibodies exert their anti-cancer effects through several mechanisms:

• Direct neutralization:

  • High-affinity MAbs neutralize the pro-tumor effects of extracellular AGR2 in cancer models

  • Inhibit AGR2-mediated cell adhesion, migration, and binding to putative cell surface partners such as LYPD3

• Immune system redirection (for bispecific antibodies):

  • AGR2xPD1 BsAb redirects cytotoxic T-cells to AGR2-expressing tumor cells

  • Enhances T-cell activation when co-cultured with target cells

  • Recruits T-cells to AGR2-overexpressing cancer cells

  • Induces higher expression of cytolytic proteins in T-cells

• Tumor microenvironment modulation:

  • Enhances co-localization of AGR2 and PD1 in AGR2-overexpressing tumor sites

  • Mediates higher attachment and infiltration of CD3+ CD8+ cytotoxic T-cells into the tumor microenvironment

  • Inhibits AGR2-induced angiogenesis and tumor growth

  • Blocks PDL1 upregulation induced by AGR2 through the EGFR signaling pathway

How can bispecific antibodies targeting AGR2 enhance immunotherapy approaches?

The novel AGR2xPD1 bispecific antibody represents an advanced approach to cancer immunotherapy by:

• Dual-targeting strategy:

  • Simultaneously targets AGR2 (on tumor cells) and PD1 (on T-cells)

  • Creates a physical bridge between cancer cells and T-cells

• Enhanced T-cell effects:

  • Increases attachment of T-cells to cancer cells

  • Enhances T-cell-mediated cytotoxicity in co-culture systems

  • Promotes T-cell activation specifically in the presence of target cells

• Improved tumor infiltration:

  • Mediates higher infiltration of cytotoxic T-cells into the tumor microenvironment in mouse models

  • Creates co-localization of AGR2 and PD1 at AGR2-overexpressing tumor sites

• Multiple anti-tumor mechanisms:

  • Combines direct tumor-targeting (via AGR2) with immune checkpoint inhibition (via PD1)

  • Inhibits both AGR2-induced angiogenesis and AGR2-mediated PDL1 upregulation

What are common challenges in detecting AGR2 in tissue samples?

Researchers frequently encounter these challenges when detecting AGR2:

• Variable expression across tissues:

  • AGR2 shows highly tissue-specific expression patterns

  • Strong expression in digestive tract epithelia but minimal in most other tissues

  • Expression can vary significantly between normal tissues and tumor samples

• Antigen retrieval optimization:

  • Retrieval conditions significantly impact AGR2 antibody performance

  • Different antibodies may require specific buffer systems (TE buffer pH 9.0 or citrate buffer pH 6.0)

• Distinguishing secreted versus intracellular AGR2:

  • AGR2 functions both as an intracellular protein disulfide isomerase and as a secreted factor

  • Different detection methods may be required to assess these distinct pools

• Cross-reactivity considerations:

  • AGR2 shares sequence homology with other protein disulfide isomerase family members

  • Antibody validation is critical for ensuring specificity

What factors should be considered when selecting an AGR2 antibody for specific research applications?

When selecting an AGR2 antibody, researchers should consider:

• Application compatibility:

  • Verify the antibody has been validated for your specific application (WB, IHC, IF, FC, IP)

  • Check recommended dilutions and protocols for your application

• Species reactivity:

  • Many AGR2 antibodies are human-specific or react with a limited range of species

  • The D9V2F XP® Rabbit mAb primarily reacts with human AGR2

  • Some antibodies may cross-react with mouse and rat AGR2, but this should be confirmed

• Epitope recognition:

  • Consider whether the antibody recognizes specific domains of AGR2

  • Important if studying truncated forms or specific interactions

• Clonality and source:

  • Monoclonal antibodies offer consistent lot-to-lot reproducibility

  • Recombinant antibodies provide superior consistency, continuous supply, and animal-free manufacturing

• Detection sensitivity:

  • Different antibodies may have varying sensitivity levels for detecting endogenous AGR2

  • High-affinity antibodies (picomolar range) may be required for detecting low-abundance AGR2

How can researchers validate AGR2 antibody specificity?

To ensure antibody specificity and reliable results, researchers should:

• Use multiple detection methods:

  • Confirm findings using different techniques (WB, IHC, IF, etc.)

  • Each method provides complementary information about antibody specificity

• Include appropriate controls:

  • Positive controls: A549 cells, intestinal tissues, known AGR2-expressing cancers

  • Negative controls: Normal pancreatic tissue, tissues with minimal AGR2 expression

  • Genetic controls: AGR2 knockdown or knockout models where available

• Perform peptide competition assays:

  • Pre-incubate antibody with purified AGR2 protein or peptide

  • Specific signal should be blocked or significantly reduced

• Cross-validate with multiple antibodies:

  • Use antibodies from different sources recognizing different epitopes

  • Consistent results across antibodies increase confidence in specificity

• Validate applications individually:

  • Successful use in one application (e.g., WB) doesn't guarantee performance in others (e.g., IHC)

  • Optimization may be required for each application